ANTIBODY-EVADING VIRUS VECTORS
The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.
1 - 97 . (canceled)
98 . A recombinant adeno-associated virus (AAV) capsid protein, wherein the recombinant AAV capsid protein is an AAV9 capsid protein comprising an amino acid sequence corresponding to SEQ ID NO: 9 comprising a first substitution and a second substitution, wherein the first substitution is a substitution of the amino acids corresponding to amino acids 587 to 594 in SEQ ID NO: 9 with the amino acid sequence of SEQ ID NO: 14, and wherein the second substitution is a substitution of the amino acids corresponding to amino acids 451 to 458 in SEQ ID NO: 9 with the amino acid sequence of any one of SEQ ID NOs: 159, 1376, 1377, 1378, 1379, 1380, and 2590.
99 . The recombinant AAV capsid protein of claim 98 , wherein the second substitution is a substitution of the amino acids corresponding to amino acids 451 to 458 in SEQ ID NO: 9 with the amino acid sequence of SEQ ID NO: 1379.
100 . The recombinant AAV capsid protein of claim 98 , wherein the recombinant AAV capsid protein comprises a third substitution that is a replacement of the amino acids corresponding to amino acids 491 to 492 in SEQ ID NO: 9 with a sequence selected from SS, AA, SA, and AS.
101 . An adeno-associated virus (AAV) vector comprising the recombinant AAV capsid protein of claim 98 .
102 . The AAV vector of claim 101 , wherein the AAV vector comprises an encapsidated nucleic acid, wherein the encapsidated nucleic acid is encapsidated by the AAV capsid protein.
103 . The AAV vector of claim 102 , wherein the encapsidated nucleic acid comprises at least one terminal repeat sequence.
104 . The AAV vector of claim 103 , wherein the encapsidated nucleic acid further comprises a heterologous nucleic acid sequence.
105 . The AAV vector of claim 104 , wherein the encapsidated nucleic acid comprises inverted terminal repeat (ITR) sequences located 3′ and 5′ of the heterologous nucleic acid sequence.
106 . The AAV vector of claim 105 , wherein the heterologous nucleic acid sequence encodes a polypeptide.
107 . The AAV vector of claim 106 , wherein the polypeptide is a therapeutic polypeptide, an immunogenic polypeptide, or a nuclease.
108 . The AAV vector of claim 107 , wherein polypeptide is a nuclease, and the nuclease is a Cas9 nuclease or a Cpf1 nuclease.
109 . The AAV vector of claim 104 , wherein the heterologous nucleic acid sequence encodes an untranslated RNA.
110 . The AAV vector of claim 109 , wherein the untranslated RNA is a guide RNA.
111 . The AAV vector of claim 109 , wherein the untranslated RNA is an antisense RNA, a ribozyme, or an interfering RNA.
112 . A pharmaceutical composition comprising the AAV vector of claim 101 and a pharmaceutically acceptable carrier.
113 . A method of introducing a nucleic acid into a cell, comprising contacting the cell with the AAV vector of claim 101 .
114 . A nucleic acid comprising a nucleic acid sequence encoding the recombinant AAV capsid protein of claim 98 .
115 . An expression vector comprising a nucleic acid sequence encoding the recombinant AAV capsid protein of claim 98 .
116 . A cell comprising the nucleic acid of claim 114 .
117 . A method of producing an adeno-associated virus (AAV) vector, the method comprising:
a. culturing a cell that comprises (i) the nucleic acid of claim 114 , (ii) a nucleic acid comprising 5′ inverted terminal repeat (ITR), a heterologous nucleic acid sequence, and a 3′ ITR, and (iii) AAV sequences sufficient for replication and encapsidation of nucleic acid, wherein the cell is cultured under conditions such that it produces the AAV vector; and
b. collecting the AAV vector from the cell.